This Webinar is titled “Transfusion indications for Sickle Cell Disease and Thalassemia patients. How to optimize them”. Sickle cell disease (SCD) and B-Thalassemia are inherited disorders. SCD affects hemoglobin and is characterized to distort red blood cells with a sickle shape which causes anemia, infections, stroke and pain. B-thalassemia reduces the production of hemoglobin causing pale skin, weakness and fatigue among others due to the anemia.

Simple or exchange transfusions are chronic treatments in individuals with SCD and B-Thalassemia. Patients need RBC transfusions to prevent complications or during the treatment of acute complications. Transfusion therapy is a requirement for survival and is used to suppress ineffective erythropoiesis and improve growth and development in children.

Regular RBC transfusions may result in alloimmunization. Consequences of alloimmunization are associated with hemolytic transfusion reactions, autoantibody formation, and delays in patient care when identification of compatible units becomes a challenge. The result is a short survival of the RBCs transfused causing an unsuccessful transfusion.

Throughout this webinar, you will learn more about these diseases, and why those patients need regular transfusions. You will also discover the latest guidelines and recommendations to treat those patients from the transfusion point-of-view and how to choose the best way to maximize their transfusion benefits.


  1. Review of the SCD and Thalassemia diseases: state-of-the-art, prevalence, current treatments, needs to be transfused
  2. Effects of alloimmunization in these patients and how to prevent it
  3. Current guidelines to treat and better support these patients
Dr. Greg Denomme
Laboratory Director, GRIFOLS San Marcos Lab, Tx (USA)

Dr. Denomme is a clinical and academic trained scientist. He has worked in transfusion medicine his entire career; initially obtaining Canadian medical lab scientist credentials with advanced certification in immunohematology. Following his clinical training, he obtained a doctorate in microbiology and immunology at the University of Western Ontario and held two postdoctoral fellowships; one in platelet immunology at the Canadian Red Cross Society, and the other in Pathology and Molecular Medicine at McMaster University, Canada. Dr. Denomme ‘s work experience includes supervisory, managerial, and directorships at small community-based hospitals to academic tertiary care facilities and blood centers. He has held academic appointments in Laboratory Medicine and Pathology, promoting to Associate Professor at the University of Toronto, and was Senior Director of Immunohematology and Innovation at Versiti Blood Center of Wisconsin, where he held a senior investigator position with Versiti’s Blood Research Institute. Presently, he is Laboratory Director and Head of Research and Development at Grifols Laboratory Services in San Marcos Texas. His applied research integrates blood group genetics and immunohematology to the study of blood group antigen expression and the impact on immune-mediated hemolytic disorders.

Dr. Denomme is a recipient of the North Carolina Association of Blood Bankers, Petteway-Shepherd Award, the AABB Sally Frank Award and Lectureship, a Harvard Medical School Margot S. Kruskall Lectureship, the Michigan Association of Blood Banks Kay Beattie Lectureship, and the Canadian Blood Services Kenneth J Fyke Award for innovation in health services. He is a distinguished fellow of the Canadian Society for Medical Laboratory Sciences. Dr. Denomme has published over 100 peer-reviewed manuscripts along with a dozen or so book, book chapters, and monographs.


Title: Grifols Academy of Transfusion Medicine Webinar: Transfusion indications for Sickle Cell Disease and Thalassemia patients. How to optimize them by Dr. Greg Denomme
Date: July 6th, 2:00PM CEST
1 hour

Live webinar

Register Now

Already Registered?
Data controller Grifols, S.A.
Purpose To manage and control your registration and participation in webinars
Legal basis Consent
Recipients Grifols group companies and other third parties
Rights To access, rectify and erase personal data, as well as other rights detailed in the additional information section
Additional information For additional information on how Grifols processes your personal data, please, click here